CRISPR and Cancer

Researchers have identified ARL11 as a critical factor in resistance to PARP inhibitor therapy through a genome-wide CRISPR activation screen,...

A Spanish study explores a CRISPR-based gene therapy approach for Ewing sarcoma. The in vivo treatment reduced tumour growth in mice, with no...

Researchers at ETH Zürich have introduced a combined base and prime editing approach to explore the mutational landscape of the epithelial growth...

A new method for directly editing T-cells in lymph nodes using CRISPR-Cas9 aims to enhance immune checkpoint blockade (ICB) cancer therapies. The...

American researchers have used transcriptome-wide CRISPR-Cas13 screens in multiple human cell lines to identify 46 universally essential and more than...

The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...

Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by RenJi Hospital (Shanghai), The University of Texas MD...